UMediC Group Bhd reported a profit after tax (PAT) of RM6.2 million for the nine-month period ended April 30, 2026 (9M26), supported by steady revenue growth and stronger margins driven by its medical devices marketing and distribution segment.
For the cumulative period, revenue also rose 10.3% year-on-year to RM40 million, while gross profit increased 17.7% to RM17.9 million, reflecting improved contribution from both its distribution operations and manufacturing activities.
In the third quarter alone, the medical devices group recorded revenue of RM12.4 million, up 6.8% from a year earlier, with PAT coming in at RM1.9 million. Gross profit for the quarter grew at a faster pace of 25.1%, indicating improved operational efficiency and product mix.
UMediC Executive Director and Chief Executive Officer Lim Taw Seong said the group’s performance was supported by continued execution of its long-term growth strategy, including expansion in manufacturing capacity and deeper penetration into hospital networks.
He noted that the completion of its Batu Kawan manufacturing facility and acquisition of additional industrial land would enhance production capabilities for proprietary healthcare products, supporting both domestic and international demand.
The group also highlighted its growing presence in the neurology segment, particularly in treatments for Parkinson’s disease and epilepsy, as well as its introduction of vagus nerve stimulation therapy in Malaysia.
UMediC said demographic trends, including an ageing population and rising healthcare demand, are expected to support long-term growth as it expands into complementary healthcare services and strengthens its product portfolio.
